ProbeChem®
*Expedite Your Scientific Research*

WWW.PROBECHEM.COM

# Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists.

| | | |
|---|---|---|
| **Product Name** | : | ABT-702 |
| **Cat. No.** | : | PC-38790 |
| **CAS No.** | : | 214697-26-4 |
| **Molecular Formula** | : | $C_{22}H_{19}BrN_6O$ |
| **Molecular Weight** | : | 463.339 |
| **Target** | : | Adenosine Kinase (AdK) |
| **Solubility** | : | 10 mM in DMSO |




## Biological Activity

ABT-702 is a potent, selective, orally active, non-nucleoside **adenosine kinase** (ADK) inhibitor with IC50 of 1.7 nM.
ABT-702 displays several orders of magnitude selectivity over other sites of ADO interaction (A(1), A(2A), A(3) receptors, ADO transporter, and ADO deaminase), and 1300- to 7700-fold selective for ADK compared with a number of other neurotransmitter and peptide receptors, ion channel proteins, neurotransmitter/nucleoside reuptake sites, and enzymes, including COX-1 and -2.
ABT-702 is orally active and fully efficacious in reducing acute somatic nociception (ED50 = 8 micromol/kg i.p.; 65 micromol/kg p.o.) in the mouse hot-plate assay.
ABT-702 also dose dependently reduced nociception in the phenyl-p-quinone-induced abdominal constriction assay.
ABT-702 dispalyed analgesic and anti-inflammatory properties in vivo.

## References

Kowaluk EA, et al. ***J Pharmacol Exp Ther.*** 2000 Dec;295(3):1165-74.

Lee CH, et al. ***J Med Chem***. 2001 Jun 21;44(13):2133-8.

Suzuki R, et al. ***Br J Pharmacol***. 2001 Apr;132(7):1615-23. al.

Jarvis MF, et al. ***J Pharmacol Exp Ther***. 2000 Dec;295(3):1156-64.



E-mail: tech@probechem.com